Abstract
Background SARS-CoV-2 viral entry may disrupt angiotensin II (Ang II) homeostasis in part via ACE2 downregulation, potentially contributing to COVID-19 induced lung injury. Preclinical models of viral pneumonias that utilize ACE2 demonstrate Ang II type 1 receptor (AT1R) blockade mitigates lung injury, though observational COVID-19 data addressing the effect of AT1R blockade remain mixed.
Methods Multicenter, blinded, placebo-controlled randomized trial of losartan (50 mg PO twice daily for 10 days) versus placebo. Hospitalized patients with COVID-19 and a respiratory sequential organ failure assessment score of at least 1 and not already taking a renin-angiotensin-aldosterone system (RAAS) inhibitor were eligible. The primary outcome was the imputed partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio at 7 days. Secondary outcomes included ordinal COVID-19 severity, oxygen, ventilator, and vasopressor-free days, and mortality. Losartan pharmacokinetics (PK) and RAAS components [Ang II, angiotensin-(1–7) (Ang-(1–7)), ACE, ACE2] were measured in a subgroup of participants.
Findings From April 2020 - February 2021, 205 participants were randomized, 101 to losartan and 104 to placebo. Compared to placebo, losartan did not significantly affect PaO2/FiO2 ratio at 7 days [difference of -24.8 (95% -55.6 to 6.1; p=0.12)]. Losartan did not improve any secondary clinical outcome, but worsened vasopressor-free days. PK data were consistent with appropriate steady-state concentrations, but we observed no significant effect of losartan on RAAS components.
Interpretation Initiation of orally administered losartan to hospitalized patients with COVID-19 and acute lung injury does not improve PaO2 / FiO2 ratio at 7 days. These data may have implications for ongoing clinical trials.
Trial Registration Losartan for Patients With COVID-19 Requiring Hospitalization (NCT04312009), https://clinicaltrials.gov/ct2/show/NCT04312009
Competing Interest Statement
Funding: The study was primarily funded by the Bill and Melinda Gates Foundation. AMS reports support from (NIH NHLBI K23HL148394; L40HL148910; R01HL146818); Pharmacokinetic data analyses were supported by NIH R01AI124965 (CVF). The funder had no role in the analysis, interpretation of results, or decision to publish.
Clinical Trial
NCT04312009
Funding Statement
Funding: The study was primarily funded by the Bill and Melinda Gates Foundation. AMS reports support from (NIH NHLBI K23HL148394; L40HL148910; R01HL146818); Pharmacokinetic data analyses were supported by NIH R01AI124965 (CVF). The funder had no role in the analysis, interpretation of results, or decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by a central institutional review board (Advarra, Pro00042757) and conducted following good clinical practice guidelines under the oversight of an independent data safety monitoring board. All participants or their legally authorized representatives (LARs) provided written electronic informed consent. The trial was conducted under the authority of the Food and Drug Administration (IND 148365) and registered on clinicaltrials.gov prior to initialization (NCT043112009).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interests: The authors have no financial conflicts of interest to disclose.
Funding: The study was primarily funded by the Bill and Melinda Gates Foundation. AMS reports support from (NIH NHLBI K23HL148394; L40HL148910; R01HL146818); Pharmacokinetic data analyses were supported by NIH R01AI124965 (CVF). The funder had no role in the analysis, interpretation of results, or decision to publish.
Critical revisions of the manuscript: All authors
Data Availability
Deidentified data will be fully available upon peer reviewed publication at the Data Repository for the University of Minnesota
